BioAI benchmarks may be leaking seen molecules into supposedly unseen tests
DeryaTR_ · x · 2026-07-22
A benchmark problem may be holding back BioAI progress: according to the quoted thread, the standard “exams” used for small-molecule activity prediction often are not truly out-of-sample.
The key claim is that many drug-discovery benchmarks contain molecules the models have effectively already seen, which makes them a poor test of generalization. The thread argues that better evaluation design is necessary if BioAI is going to advance meaningfully.
More from Research
- New paper: Absolute pose estimation from affine cues and gravity direction — ducha_aiki · 2026-09-11
- LoMa Paper Ships REALLY HardPairs Dataset, Accepted at ECCV 2026 — ducha_aiki · 2026-09-11
- Johns Hopkins Launches Full-Stack Hands-on Robot Learning Class with SO-101 Arm Kits — _krishna_murthy · 2026-09-11
- SyncWorld: In-Context Robot World Model Simulates Unseen Views and Embodiments Zero-Shot — ChongZzZhang · 2026-09-11
- A 3D Pose Dataset for Dogs Released — ducha_aiki · 2026-09-11
- Five tells that still make AI video read as AI, from physics glitches to missing operators — NewPhoneWhotiz · 2026-09-11